CY1118200T1 - Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης - Google Patents
Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσηςInfo
- Publication number
- CY1118200T1 CY1118200T1 CY20161101131T CY161101131T CY1118200T1 CY 1118200 T1 CY1118200 T1 CY 1118200T1 CY 20161101131 T CY20161101131 T CY 20161101131T CY 161101131 T CY161101131 T CY 161101131T CY 1118200 T1 CY1118200 T1 CY 1118200T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- polynucleotides
- polypeptides
- compositions
- latent tuberculosis
- Prior art date
Links
- 206010065048 Latent tuberculosis Diseases 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 101100445599 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) espA gene Proteins 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8372008P | 2008-07-25 | 2008-07-25 | |
| PCT/EP2009/059580 WO2010010177A1 (en) | 2008-07-25 | 2009-07-24 | Novel compositions and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118200T1 true CY1118200T1 (el) | 2017-06-28 |
Family
ID=41217660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101131T CY1118200T1 (el) | 2008-07-25 | 2016-11-04 | Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20110117119A1 (OSRAM) |
| EP (1) | EP2315773B1 (OSRAM) |
| JP (1) | JP5873332B2 (OSRAM) |
| KR (1) | KR20110044883A (OSRAM) |
| CN (1) | CN102164952B (OSRAM) |
| AU (1) | AU2009273130B2 (OSRAM) |
| BR (1) | BRPI0916703A2 (OSRAM) |
| CA (1) | CA2731499C (OSRAM) |
| CO (1) | CO6341637A2 (OSRAM) |
| CY (1) | CY1118200T1 (OSRAM) |
| DK (1) | DK2315773T3 (OSRAM) |
| EA (1) | EA024826B1 (OSRAM) |
| ES (1) | ES2602430T3 (OSRAM) |
| HR (1) | HRP20161458T1 (OSRAM) |
| HU (1) | HUE031044T2 (OSRAM) |
| IL (1) | IL210559A0 (OSRAM) |
| LT (1) | LT2315773T (OSRAM) |
| MX (1) | MX2011000983A (OSRAM) |
| PL (1) | PL2315773T3 (OSRAM) |
| PT (1) | PT2315773T (OSRAM) |
| SG (1) | SG192456A1 (OSRAM) |
| SI (1) | SI2315773T1 (OSRAM) |
| UA (1) | UA107330C2 (OSRAM) |
| WO (1) | WO2010010177A1 (OSRAM) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69941545D1 (de) * | 1998-11-04 | 2009-11-26 | Isis Innovation | Tuberkulose diagnose test |
| NO2315597T3 (OSRAM) * | 2008-07-25 | 2018-01-20 | ||
| EP2315834B1 (en) | 2008-07-25 | 2018-06-13 | GlaxoSmithKline Biologicals S.A. | The tuberculosis rv2386c protein, compositions and uses thereof |
| EP2156945A1 (en) | 2008-08-13 | 2010-02-24 | Novelis Inc. | Clad automotive sheet product |
| TR201903223T4 (tr) | 2009-04-24 | 2019-03-21 | Statens Seruminstitut | Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı. |
| US8932600B2 (en) * | 2010-01-27 | 2015-01-13 | Glaxosmithkline Biologicals S.A. | Modified tuberculosis antigens |
| KR102341026B1 (ko) * | 2013-09-27 | 2021-12-21 | 코덱시스, 인코포레이티드 | 구조에 기반한 예측 모델링 |
| SG11201601695WA (en) | 2013-09-27 | 2016-04-28 | Codexis Inc | Automated screening of enzyme variants |
| GB201405921D0 (en) * | 2014-04-02 | 2014-05-14 | Glaxosmithkline Biolog Sa | Novel methods for inducing an immune response |
| CN106546737A (zh) * | 2016-10-24 | 2017-03-29 | 广州迪澳医疗科技有限公司 | 一种体外检测活动性结核的方法 |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| GB201707700D0 (en) | 2017-05-12 | 2017-06-28 | Glaxosmithkline Biologicals Sa | Dried composition |
| US12016919B2 (en) | 2017-05-30 | 2024-06-25 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
| CA3083078A1 (en) | 2017-12-01 | 2019-06-06 | Glaxosmithkline Biologicals Sa | Saponin purification |
| BR112021019669A2 (pt) | 2019-04-12 | 2021-12-07 | C4 Therapeutics Inc | Composto, composição farmacêutica, método para tratar um transtorno, composto para uso na produção de um medicamento, e, uso de um composto no tratamento de um transtorno |
| BR112021024363A2 (pt) | 2019-06-05 | 2022-03-22 | Glaxosmithkline Biologicals Sa | Purificação de saponina |
| CN115073612B (zh) * | 2022-06-22 | 2024-09-27 | 宁夏大学 | 一种结核分枝杆菌Zera-71cA蛋白纳米颗粒、制备方法及其用途 |
| GB202318595D0 (en) * | 2023-12-05 | 2024-01-17 | Sec Dep For Environment Food And Rural Affairs Acting Through Animal And Plant Health Agency | Diagnostic proteins and reagents |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6613881B1 (en) * | 1997-05-20 | 2003-09-02 | Corixa Corporation | Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use |
| CZ302870B6 (cs) * | 1998-04-07 | 2011-12-28 | Corixa Corporation | Polynukleotid, polypeptid, farmaceutický prostredek, vakcínový prostredek a jejich použití k lécbe a prevenci infekce tuberkulózou |
| WO2001062893A2 (en) * | 2000-02-25 | 2001-08-30 | Corixa Corporation | Compounds and methods for diagnosis and immunotherapy of tuberculosis |
| AU6867801A (en) * | 2000-06-20 | 2002-01-02 | Corixa Corp | Fusion proteins of mycobacterium tuberculosis |
| AU2002219338B2 (en) * | 2001-01-08 | 2006-12-14 | Oxford Immunotec Limited | Assay to determine efficacy of treatment for mycobacterial infection |
| AU2002302919A1 (en) * | 2001-02-22 | 2002-10-03 | Institut Pasteur | Comparative mycobacterial geneomics as a tool for identifying targets for the diagnosis, prophylaxis or treatment of mycobacterioses |
| US20030236393A1 (en) * | 2002-03-22 | 2003-12-25 | United States Of America Dept Of Vetrans Affairs | Virulence genes of M. marinum and M. tuberculosis |
| EP1781313A4 (en) * | 2004-06-17 | 2009-08-26 | Beckman Coulter Inc | MYCOBACTERIUM TUBERCULOSIS EPITOPES AND METHODS OF USE |
| EP1877426B1 (en) | 2005-04-29 | 2012-02-01 | GlaxoSmithKline Biologicals SA | Method for preventing or treating m tuberculosis infection |
| AU2006261445B2 (en) * | 2005-06-23 | 2011-03-31 | Statens Serum Institut | Tuberculosis vaccines comprising antigens expressed during the latent infection phase |
| WO2008007942A1 (en) * | 2006-07-10 | 2008-01-17 | Het Nederlands Kanker Instituut | Means and methods for manipulating sequential phagolysomal-cytosolic translocation of mycobacteria, and uses thereof |
| EP2087128A4 (en) * | 2006-11-01 | 2009-11-04 | Immport Therapeutics Inc | COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES |
| TR201903223T4 (tr) * | 2009-04-24 | 2019-03-21 | Statens Seruminstitut | Reaktivasyonu önlemek üzere bir tüberküloz TB aşısı. |
| US8932600B2 (en) | 2010-01-27 | 2015-01-13 | Glaxosmithkline Biologicals S.A. | Modified tuberculosis antigens |
-
2009
- 2009-07-24 SI SI200931561A patent/SI2315773T1/sl unknown
- 2009-07-24 JP JP2011519185A patent/JP5873332B2/ja not_active Expired - Fee Related
- 2009-07-24 EA EA201100072A patent/EA024826B1/ru not_active IP Right Cessation
- 2009-07-24 HR HRP20161458TT patent/HRP20161458T1/hr unknown
- 2009-07-24 CA CA2731499A patent/CA2731499C/en active Active
- 2009-07-24 DK DK09781052.7T patent/DK2315773T3/en active
- 2009-07-24 PT PT97810527T patent/PT2315773T/pt unknown
- 2009-07-24 CN CN200980138400.6A patent/CN102164952B/zh active Active
- 2009-07-24 BR BRPI0916703A patent/BRPI0916703A2/pt not_active IP Right Cessation
- 2009-07-24 HU HUE09781052A patent/HUE031044T2/en unknown
- 2009-07-24 US US13/055,801 patent/US20110117119A1/en not_active Abandoned
- 2009-07-24 KR KR1020117004640A patent/KR20110044883A/ko not_active Ceased
- 2009-07-24 SG SG2013050562A patent/SG192456A1/en unknown
- 2009-07-24 MX MX2011000983A patent/MX2011000983A/es active IP Right Grant
- 2009-07-24 AU AU2009273130A patent/AU2009273130B2/en not_active Ceased
- 2009-07-24 WO PCT/EP2009/059580 patent/WO2010010177A1/en not_active Ceased
- 2009-07-24 UA UAA201100363A patent/UA107330C2/uk unknown
- 2009-07-24 EP EP09781052.7A patent/EP2315773B1/en active Active
- 2009-07-24 LT LTEP09781052.7T patent/LT2315773T/lt unknown
- 2009-07-24 ES ES09781052.7T patent/ES2602430T3/es active Active
- 2009-07-24 PL PL09781052T patent/PL2315773T3/pl unknown
-
2011
- 2011-01-11 IL IL210559A patent/IL210559A0/en unknown
- 2011-01-27 CO CO11009231A patent/CO6341637A2/es not_active Application Discontinuation
-
2013
- 2013-06-28 US US13/930,587 patent/US9795663B2/en not_active Expired - Fee Related
-
2016
- 2016-11-04 CY CY20161101131T patent/CY1118200T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0916703A2 (pt) | 2019-12-24 |
| PT2315773T (pt) | 2016-11-23 |
| DK2315773T3 (en) | 2016-12-12 |
| CN102164952A (zh) | 2011-08-24 |
| HRP20161458T1 (hr) | 2016-12-16 |
| MX2011000983A (es) | 2011-03-02 |
| AU2009273130B2 (en) | 2014-10-16 |
| SG192456A1 (en) | 2013-08-30 |
| US20110117119A1 (en) | 2011-05-19 |
| EA201100072A1 (ru) | 2011-10-31 |
| CA2731499C (en) | 2017-01-10 |
| SI2315773T1 (sl) | 2016-12-30 |
| JP2011528895A (ja) | 2011-12-01 |
| CO6341637A2 (es) | 2011-11-21 |
| US20140178423A1 (en) | 2014-06-26 |
| KR20110044883A (ko) | 2011-05-02 |
| WO2010010177A1 (en) | 2010-01-28 |
| PL2315773T3 (pl) | 2017-07-31 |
| US9795663B2 (en) | 2017-10-24 |
| LT2315773T (lt) | 2016-11-10 |
| EP2315773B1 (en) | 2016-08-24 |
| JP5873332B2 (ja) | 2016-03-01 |
| CN102164952B (zh) | 2016-05-25 |
| AU2009273130A1 (en) | 2010-01-28 |
| EP2315773A1 (en) | 2011-05-04 |
| UA107330C2 (uk) | 2014-12-25 |
| CA2731499A1 (en) | 2010-01-28 |
| ES2602430T3 (es) | 2017-02-21 |
| IL210559A0 (en) | 2011-03-31 |
| EA024826B1 (ru) | 2016-10-31 |
| HUE031044T2 (en) | 2017-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118200T1 (el) | Πολυπεπτιδια, πολυνουκλεοτιδια και συνθεσεις για χρηση στη θεραπεια λανθανουσας φυματιωσης | |
| CY1121632T1 (el) | Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης | |
| CY1119737T1 (el) | Νεες συνθεσεις και μεθοδοι | |
| CY1119789T1 (el) | Cgrp αντισωματα | |
| CY1121687T1 (el) | Αλληλουχιες αμινοξεων που κατευθυνονται εναντι των πρωτεϊνων φακελου ενος ioy και πολυπεπτιδια που τις περιεχουν για τη θεραπευτικη αντιμετωπιση ιικων νoσων | |
| CY1122564T1 (el) | Μορια δεσμευσης μονhς αλυσιδας που περιλαμβανουν ν-τελικο αβρ | |
| CY1121900T1 (el) | Ανθρωποποιημενο αντισωμα αντι καλλικρεϊνης-2 | |
| CY1120772T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| CY1122195T1 (el) | Πολυπεπτιδια συντηξης σερπινης και μεθοδοι χρησης αυτων | |
| CY1121934T1 (el) | Αντισωματα anti-fcrn | |
| CY1107042T1 (el) | Ανασυνδυασμενη πρωτεϊνη που φερει επιτοπους του ανθρωπινου ιου των θηλωματων που εχουν εισαχθει σε μια πρωτεϊνη αδενυλικης κυκλασης ή τμηματα αυτης, θεραπευτικες χρησεις αυτων | |
| CY1120471T1 (el) | Αντισωματα κατα του cd70 | |
| EA201171494A1 (ru) | Миметики белка smac | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
| CY1116646T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| CY1121964T1 (el) | Αντισωματα εναντιον toy csf-1r | |
| MX2016004579A (es) | Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas. | |
| DOP2014000083A (es) | Inmunoenlazadores dirigidos contra el tnf | |
| EA201400568A1 (ru) | Альбуминсвязывающие антитела и их связывающие фрагменты | |
| CY1117697T1 (el) | Σταθεροποιημενα απο δεσμους δισουλφιδιων λειτουργικα ευδιαλυτα ετεροδιμερη toy mhc ταξης ii | |
| CY1119149T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| ECSP12012272A (es) | Proteínas que se unen al tnf-? | |
| CY1120055T1 (el) | Αντικαρκινικη πρωτεϊνη συντηξης | |
| CY1118153T1 (el) | Αγωγη μικροβιακων μολυνσεων |